Therapeutic Areas · Women's Health
Women's health research demands specialized expertise across maternal, reproductive and gynecological medicine, along with sensitive recruitment and safety considerations.
Overview
Women's health research demands specialized expertise across maternal, reproductive and gynecological medicine, along with sensitive recruitment and safety considerations.
Guosa Life Sciences supports women's health programs with dedicated networks and tailored operational strategies.
Areas of Expertise
Specialized Capabilities
Why GLS
Our integrated enterprise combines scientific depth, operational excellence and collaborative partnerships to support development across diverse and demanding research environments.
The capability
We support women’s health programs across obstetrics, gynecology, urogynecology, fertility, endometriosis, menopause and maternal-fetal medicine, including the maternal health research that carries a substantial share of the global disease burden.
Studies in this area frequently involve populations that are excluded by default elsewhere, which places the risk-benefit reasoning at the center of design rather than at its margins. Protocols need to state clearly why inclusion is justified and how risk is managed, because ethics committees will ask.
Regulatory considerations
Contraception and pregnancy requirements shape recruitment, retention and the consent conversation. Protocols specify acceptable contraceptive methods, testing schedules and the actions required on a positive result, and these specifications must be workable in the actual study population rather than transposed from another region. Requirements that assume access to particular methods will fail in settings where that access is not reliable.
Where pregnancy exposure occurs, whether by protocol or inadvertently, follow-up obligations extend beyond the study period and often beyond the mother to the infant. Pregnancy exposure registries and long-term follow-up commitments need consent language, data collection and retention planning designed for that duration from the outset, and the requirements differ enough between jurisdictions that a single global approach usually needs local adaptation.
How an engagement runs
Population, risk-benefit justification, contraception and pregnancy testing requirements specified against the actual study setting.
Consent materials, site training on pregnancy reporting, and follow-up mechanisms established before enrollment.
Pregnancy reporting monitored, exposure follow-up initiated promptly, retention managed across long follow-up periods.
Analysis with documented exposure outcomes and continuing follow-up commitments.
What you receive
A protocol with documented risk-benefit justification. Workable contraception and testing specifications. Pregnancy exposure reporting and follow-up records. Long-term follow-up continuity plan.
Evidence and context
Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.
Other Therapeutic Areas
Preventive and therapeutic vaccines, pandemic preparedness.
ExploreEarly-phase through global Phase III.
ExploreComplex endpoints and assessment.
ExploreMedical and aesthetic dermatology.
ExploreMedical and aesthetic dermatology.
ExploreAsthma, COPD and acute infection.
ExploreCardiovascular, diabetes and metabolic.
ExploreSmall, dispersed populations.
ExploreDevice and diagnostic studies.
ExplorePopulation and vaccination programs.
ExploreDiscuss your women's health program with our multidisciplinary team.